Moreover, some researchers used scRNA-seq to study the dynamic change of peripheral blood T cell clones in NSCLC patients receiving PD-1 inhibitors (45), and found that the number of a CD4+T cell clone related to tumor significantly dropped upon tumor progression, and the proportion of PD-1+T cells also decreased significantly. The gene discussed is PDCD1; the disease is neoplasm.